Insights Into Vepdegestrant (ARV-471): The First-in-Class Estrogen Receptor Proteolysis-Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer.

vepdegestrant (ARV-471) - Arvinas, Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/41866773

Bin Tian; Bingxing Zhang; Changhua Ke; Chao Tang; Chengyuan Liang; Juan Xia; Lei Tian; Meiling He; Meiyan Wei; Mengxin Chen; Mengzhou Wang; Qiannan Zhang; Wen Wang; Xintao Deng; Yunfei Zhang

Mar 25, 2026